IGFBP3 and chronic kidney disease: Other biomarkers (e.g., SUPAR) and composite tests that incorporate other plasma biomarkers (apolipoprotein A-IV, CD5 antigen-like, IGF-binding protein 3) and some clinical data features have been shown to accurately predict incident CKD in individuals with type 2 diabetes; however, this does not exclude other approaches that include additional biomarkers and novel methods of data analysis [41–43].